Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pionERA Breast Cancer
2022-502980-39-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Giredestrant + CDK4/6 inhibitor with Fulvestrant + CDK4/6 inhibitor (2 arms). Primary endpoint: Progression-free survival in ESR1-mutated subgroup and full analysis set. Planned start Jan 2024; status: authorised.
02
Drugs
giredestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-502980-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502980-39-00.